{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:35:32Z","timestamp":1734500132897,"version":"3.30.2"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:00:00Z","timestamp":1082592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p><jats:bold>Aim\u2002<\/jats:bold>To compare the rate of ventricular arrhythmia, sudden death and unexplained or unattended death among users of thioridazine and haloperidol.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>Observational cohort study of thioridazine and haloperidol users in the UK General Practice Research Database (GPRD) using data from 1987 through 29\u2003June 2000. Patients were followed for 30\u2003days following each study prescription. The event of interest was a diagnosis of ventricular arrhythmia, sudden death, or unexplained or unattended death. Cox regression was used to calculate rate ratios (RRs) and 95% confidence intervals (CIs), to examine potential confounding factors, and to examine dose\u2013response relationships.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>Use of thioridazine and haloperidol in the GPRD was primarily in older patients, at low dose (median daily dose 31\u2003mg thioridazine, 1.8\u2003mg haloperidol). There was no association between thioridazine use and the rate of ventricular arrhythmia, sudden death, and unexplained or unattended death (adjusted RR 0.9, 95% CI 0.7, 1.1). The rate did not appear to increase with dose for either drug over the range observed.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold>These results suggest that low\u2010dose thioridazine and haloperidol have similar cardiac safety.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2004.02098.x","type":"journal-article","created":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T08:09:15Z","timestamp":1087805355000},"page":"81-87","source":"Crossref","is-referenced-by-count":12,"title":["Comparative cardiac safety of low\u2010dose thioridazine and low\u2010dose haloperidol"],"prefix":"10.1111","volume":"58","author":[{"given":"Sean","family":"Hennessy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren B.","family":"Bilker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill S.","family":"Knauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary F.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale B.","family":"Glasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01627.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1155\/2002\/482953"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.16.2120"},{"key":"e_1_2_6_5_2","unstructured":"Briefing document for Zeldox capsules submitted by Pfizer Inc. to the US Food Drug Administration 2000;http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3619b1a.pdfaccessed25 May 2003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/archinte.1997.00440380123013","article-title":"Torsade de pointes and low\u2010dose oral haloperidol","volume":"157","author":"Jackson T","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1001\/jama.1983.03330450061027","article-title":"Thioridazine\u2010induced torsade de pointes. Successful therapy with isoproterenol","volume":"249","author":"Kemper AJ","year":"1983","journal-title":"JAMA"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","DOI":"10.1002\/0470842555","volume-title":"Pharmacoepidemiology","author":"Strom BL.","year":"2000"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1161"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7372.1070"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/0470842555.ch19"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00701.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00885.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00241-7"},{"key":"e_1_2_6_15_2","unstructured":"SmithP.United Kingdom death certificates: a resource for geneologists and historians 2002;12\u20134.http:\/\/www.paul_smith.doctors.org.uk\/UKDeathCertificates.htm"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530340058030"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.5.401"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR.","year":"1972","journal-title":"J R Stat Soc (B)"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116813"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6895.32"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.6.748"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4301.098254"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/026988110201600411","article-title":"QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients","volume":"16","author":"Lerena A","year":"2002","journal-title":"J Psychopharmacol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02035-3"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2004.02098.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2004.02098.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:45:06Z","timestamp":1734453906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2004.02098.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1365-2125.2004.02098.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02098.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2004,6,4]]}}}